Sleep Apnea and Atrial Fibrillation: CPAP and Recurrence

Sleep-disordered breathing is increasingly recognised as a modifiable contributor to atrial fibrillation (AF). Repeated upper-airway obstruction, intermittent hypoxaemia and surges in sympathetic activity can promote atrial stretch, inflammation, electrical instability and structural remodelling. These processes may influence the onset of AF and the likelihood that it returns after cardioversion or catheter ablation.

The relationship between sleep apnea and atrial fibrillation is clinically important in Australia, where obstructive sleep apnoea (OSA) is common but frequently underdiagnosed. Continuous positive airway pressure (CPAP) can improve nocturnal breathing and may reduce arrhythmia burden in appropriately selected patients, although evidence for preventing AF recurrence remains mixed. Careful diagnosis, adherence assessment and integration with broader rhythm management are essential.

Why Sleep Apnoea Promotes Atrial Fibrillation

Obstructive apnoeas generate large negative intrathoracic pressure swings as the patient attempts to breathe against a collapsed airway. These pressure changes increase atrial wall stress and may acutely shorten atrial refractory periods. Repeated episodes also activate the sympathetic nervous system, producing surges in blood pressure and heart rate that can trigger paroxysmal AF.

Over time, intermittent hypoxaemia and reoxygenation encourage oxidative stress, endothelial dysfunction and systemic inflammation. Atrial fibrosis can then develop, creating a substrate that supports multiple re-entry wavelets. OSA is also closely associated with hypertension, obesity, diabetes, heart failure and coronary disease, all of which may independently increase AF risk.

The clinical presentation is often subtle. Loud snoring, witnessed pauses, morning headache, nocturia and excessive daytime sleepiness are useful clues, but some people with significant OSA report little sleepiness. In Australia, a patient may present to a GP in a regional town with resistant hypertension or recurrent palpitations rather than with a sleep complaint, making opportunistic screening particularly valuable.

What CPAP Changes Physiologically

CPAP splints the upper airway open throughout the respiratory cycle, reducing obstructive events, oxygen desaturation and arousal-related sympathetic activation. Effective treatment can lower nocturnal blood pressure, improve sleep quality and reduce the intrathoracic pressure swings that place mechanical stress on the atria.

These effects provide a plausible pathway for reducing AF triggers and slowing atrial remodelling. CPAP may be particularly useful when OSA coexists with obesity, hypertension or heart failure, because treatment addresses a cluster of interacting cardiovascular risks rather than an isolated sleep symptom.

CPAP is not an antiarrhythmic drug and should not be presented as a substitute for anticoagulation, rate control or rhythm-control therapy. Its potential benefit depends on regular use, adequate pressure settings and correction of mask leak. A device that is prescribed but used for only a few hours on some nights is unlikely to deliver the same cardiovascular effect as consistent treatment across the whole sleep period.

Evidence After Cardioversion And Ablation

Observational studies have frequently reported lower AF recurrence among CPAP-treated patients with OSA after electrical cardioversion or pulmonary vein isolation. Some cohorts suggest that untreated OSA is associated with earlier recurrence, more repeat procedures and a greater need for antiarrhythmic medication. These findings have helped establish sleep assessment as part of comprehensive AF care.

Randomised evidence has been less consistent. Trials in patients undergoing ablation have not uniformly demonstrated a significant reduction in recurrent AF with CPAP, particularly when recurrence is assessed using intermittent monitoring or when adherence is modest. Differences in OSA severity, AF phenotype, ablation strategy, CPAP exposure and monitoring duration make direct comparisons difficult.

The most defensible interpretation is that CPAP treats an important comorbidity and may improve rhythm outcomes, but its effect on recurrence cannot be guaranteed. Current research and themed collections, including those available through the journal’s special issues, are valuable for tracking how trial design, wearable monitoring and phenotype-based treatment are refining this question.

Selecting Patients For Sleep Assessment

Patients with recurrent AF, difficult-to-control hypertension, obesity, heart failure or unexplained nocturnal bradyarrhythmia should be considered for OSA assessment. A focused history should cover snoring, witnessed apnoeas, gasping, sleep fragmentation, daytime fatigue, alcohol intake and sedative use. Tools such as the STOP-Bang questionnaire can support triage, but they do not replace diagnostic testing.

Polysomnography remains the reference standard when there is substantial cardiorespiratory complexity, suspected central sleep apnoea, neuromuscular disease or an unexplained discrepancy between symptoms and screening results. Home sleep apnoea testing may be practical for selected adults with a high pre-test probability of uncomplicated OSA. Test choice should reflect local sleep-service capacity and the patient’s comorbidities.

Australia’s geography makes access uneven. A patient in metropolitan Sydney or Melbourne may reach a sleep physician and CPAP supplier quickly, while someone in remote Western Australia, the Northern Territory or far north Queensland may rely on home testing, visiting services and telehealth review. Indigenous Australians can experience a higher burden of sleep and cardiometabolic disease, with culturally safe care and community partnership important when discussing testing and long-term device use.

Making CPAP Work In Real Practice

Before starting treatment, clinicians should explain the relationship between airway obstruction and AF in practical terms. Patients are more likely to persist when they understand that CPAP is intended to reduce cardiovascular stress, not simply stop snoring. Mask fitting, humidification, pressure adjustment and troubleshooting should be addressed early, rather than waiting for a routine review months later.

Adherence data from the device can reveal whether treatment is being used for the full sleep period and whether residual events or leak remain problematic. Nasal congestion, claustrophobia, dry mouth, pressure intolerance and partner concerns are common barriers. Heated humidification, a different interface, nasal therapy or review by a sleep professional may improve tolerance. Weight management, limiting evening alcohol and treating nasal obstruction can complement CPAP, but should not be used to delay effective treatment when OSA is clinically significant.

Funding and equipment pathways vary across Australia. Some patients obtain devices through state or territory programmes, public hospital sleep services, the Department of Veterans’ Affairs or private purchase, while eligibility and waiting times differ. Clinicians should document the diagnosis and cardiovascular indication clearly, helping patients navigate local services rather than assuming that access is uniform. During hot Australian summers, heat, sweating and dry conditions can make mask comfort more difficult, so humidification and interface choice deserve specific attention.

Integrating CPAP With Rhythm Care

AF management should continue according to stroke risk, symptoms, left atrial size, ventricular function and patient preference. CPAP does not remove the need to assess anticoagulation, and it should not be used to justify stopping oral anticoagulants after apparent rhythm control. Blood pressure management, weight reduction, exercise, alcohol moderation and treatment of heart failure remain central components of risk-factor modification.

For patients undergoing ablation, sleep assessment can be incorporated before the procedure, with CPAP initiated or optimised when indicated. Follow-up should combine symptom review with an appropriate rhythm-monitoring strategy because silent AF is common. Consumer wearables may support detection, but device alerts require clinical interpretation and do not replace validated electrocardiographic assessment.

Medication choices also need individualisation. Pregnancy, renal impairment, structural heart disease and interactions can materially alter antiarrhythmic selection; clinicians reviewing these issues may find the discussion of antiarrhythmic therapy useful alongside sleep-apnoea management. In patients with tachycardia-bradycardia syndrome or advanced conduction disease, pacing and device follow-up may be relevant, while CPAP addresses the respiratory trigger rather than the electrical indication.

Measuring Recurrence And Long-Term Benefit

Recurrence should be defined carefully. Atrial tachyarrhythmia lasting at least 30 seconds is often used in ablation studies, but patients and clinicians may care more about symptom burden, hospitalisation, cardioversion, AF duration or quality of life. Atrial high-rate episodes detected by implanted devices also require adjudication because not every episode represents clinically meaningful AF.

A useful review includes CPAP usage hours, residual apnoea-hypopnoea index, mask leak, oxygenation where available, blood pressure, weight, alcohol exposure and rhythm records. These measures help distinguish treatment failure from inadequate exposure or a competing arrhythmogenic substrate. Recurrence soon after ablation may reflect transient inflammation, whereas late recurrence may signal progressive atrial disease or persistent risk factors.

Research should continue to clarify which patients gain the greatest rhythm benefit from CPAP. Future studies would benefit from objective adherence thresholds, longer continuous monitoring, consistent definitions of OSA and recurrence, and inclusion of rural and culturally diverse Australian populations. Until those data are available, CPAP is best presented as an important part of comprehensive cardiovascular care with a credible, but not universal, effect on AF recurrence.

Integrating sleep evaluation into AF pathways can uncover a treatable driver that might otherwise remain invisible. Clinicians, electrophysiology teams and sleep services can improve outcomes by identifying OSA early, supporting sustained CPAP use and interpreting recurrence within the patient’s wider cardiovascular profile. Explore current evidence, clinical guidance and electrophysiology research through the Journal of Arrhythmia.